Personalized Medicine

The use of an individual’s genomic makeup to ascertain the risk of contracting a disease, the prognosis of a disease, or the optimal treatment of a disease (pharmacogenomics). The basic, translational, and clinical research involved with Personalized Medicine can lead to tailored medical care based on human genetic variation, identification of new pathologic pathways in disease, and discovery of novel drugs. In the case of infection disease, the genetic variation of the pathogenic organism and the human host can be utilized.

Selected Review Articles on Personalized Medicine from the Liggett Laboratory

• Liggett SB. Pharmacogenetic applications of the Human Genome project. Nature Medicine 7:281-283, 2001.
  
  
• Liggett SB. Pharmacogenetics of b₁- and b₂-adrenergic receptors. Pharmacology 61:167-173, 2000.
  
  
• Small KM, Rathz DA, Liggett SB. Identification of adrenergic receptor polymorphisms. Methods Enzymol 343:459-475, 2002.
  
  
• Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43:381-411, 2003.
  
  
• Liggett SB. Genetically modified mouse models for pharmacogenomic research. Nature Reviews Genetics 5:657-663, 2004.
  
  
• Dorn GW II, Liggett SB. Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharmacol 76:466-480, 2009.
  
  
• Liggett SB. Pharmacogenomics of b1-adrenergic receptor polymorphisms in heart failure. Heart Failure Clinics 6:27-33, 2010.
  
  
• Palmenberg AC, Rathe JA, Liggett SB. Analysis of the complete genome sequences of human rhinovirus. J Allergy Clin Immunol 125:1190-1199, 2010.
  
  
• Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 89:366-378, 2011.

Link to the Liggett Laboratory

Link to Liggett Curriculum Vitae